Document:

Form of Restricted Stock Agreement

 Exhibit 10.03 
 FORM OF RESTRICTED STOCK AGREEMENT 
 This Restricted Stock Agreement (“Agreement”) is between Valero
Energy Corporation, a Delaware corporation (“Valero”), and                     , a Non-Employee Director of the Board of
Directors of Valero (“Director”); who agree as follows: 
 1. Introduction. Pursuant to the Valero Energy Corporation
Restricted Stock Plan for Non-Employee Directors (as may be amended, the “Director Plan”), Valero has granted              shares of its Common Stock, $.01 par value
(“Restricted Shares”) to the Director. As directed by the Director Plan, the parties enter into this Agreement to evidence the terms, conditions and restrictions applicable to the Restricted Shares. 
 2. The Director Plan, Restrictions, Vesting. The Director has read and understands the Director Plan, which is incorporated herein by reference
for all purposes, and agrees to the terms and conditions applicable to the Restricted Shares and the rights and powers of Valero as provided therein. In addition, the Director agrees as follows: 
 2.01 Except as provided in the Director Plan and this Agreement, Restricted Shares may not be sold, exchanged, pledged, hypothecated,
transferred, garnished or otherwise disposed of or alienated prior to vesting. 
 2.02 Restricted Shares granted hereunder
shall vest and accrue to the Director in the following increments:              shares on the date of the annual meeting of stockholders of Valero Energy Corporation for election of
directors of Valero (“Annual Meeting”) occurring in 2008;              shares on the date of the Annual Meeting occurring in 2009; and
             shares on the date of the Annual Meeting occurring in 2010. The restrictions may terminate prior to the expiration of such period as set forth in the Director Plan.

 2.03 The Director agrees that in lieu of certificates representing the Director’s Restricted Shares, the Restricted
Shares and the shares of Common Stock issuable in connection with the vesting of the Restricted Shares may be issued in uncertificated form pursuant to the Direct Registration Service (“DRS”) of Valero’s stock transfer agent.

 2.04 If, as the result of a stock split, stock dividend, combination of shares or any other change, including an exchange
of securities, for any reason, the Director shall be entitled to new or additional or different shares of stock or securities, such stock or securities shall be subject to the terms and conditions of the Plan and this Agreement. 
 2.05 If Restricted Shares are forfeited per the terms of the Director Plan, the stock transfer agent of Valero is instructed, upon
confirmation by the Corporate Secretary of such forfeiture, to surrender the certificates representing such shares for cancellation, or the cancel the forfeited shares from the Directors’ DRS account. 
 3. Limitation. The Director shall have no rights with respect to any Restricted Shares not expressly conferred by the Director Plan or this
Agreement. 
 4. Miscellaneous. All capitalized terms contained in this Agreement shall have the definitions set forth in the Director
Plan unless otherwise defined herein. This Agreement shall be binding upon the parties hereto and their respective beneficiaries, heirs, administrators, executors, legal representatives, and successors. 
 EFFECTIVE as of the      day of
                     2007. 
  

	
	 VALERO ENERGY CORPORATION

	
	 R. Michael Crownover, Vice President

	
	  

	 [name of non-employee director]Form of Stock Option Agreement

 Exhibit 10.04 
  

							
	Notice of Grant of Stock Option	 		  	Valero Energy Corporation
	and Option Agreement	 		  	ID: 74-1828067
		 		  	P. O. Box 696000
		 		  	San Antonio, TX 78269-6000
				
	[name of non-employee director]	 		  	Option Number:	  	00000000
		 		  	Plan:	  	RMSO
				
		 		  	ID:	  	11111111

 Effective
                    , 2007 you have been granted a Non-Qualified Stock Option to buy
             shares of the common stock of Valero Energy Corporation (the “Company”) at
$             per share. 
 The total Option price of the shares granted is
$            . 
 Your Options will vest on the first anniversary of the date the
Options were granted. 
 By your signature and the Company’s signature below, you and the Company agree that the Option referenced above is granted
under and governed by the terms and conditions of the Company’s Non-Employee Director Stock Option Plan, as amended, and the Option Agreement attached hereto, all of which are made a part of this agreement. 
 VALERO ENERGY CORPORATION 
  

							
	 By:
	 	  
	 		 	  

	R. Michael Crownover	 		 	Date
	Vice President	 		 	
			
	  
	 		 	  

	Non-Employee Director	 		 	Date

 OPTION AGREEMENT 
 Valero Energy Corporation Non-Employee Director Stock Option Plan 
 This Option Agreement (“Agreement”) is
entered into between Valero Energy Corporation, a Delaware corporation (“Valero”), and a Non-Employee Director of the Board of Directors of Valero pursuant to the terms of the Valero Energy Corporation Non-Employee Director Stock Option
Plan (as may be amended, the “Director Plan”). As used herein, Director shall mean                     . Capitalized terms
used in this Agreement but not otherwise defined in this Agreement have the meanings set forth in the Director Plan. 
 1. Grant of
Option. Valero grants to Director the option (“Option”) to purchase up to              shares of Common Stock of Valero, $.01 par value per share (“Shares”),
in accordance with the terms of this Agreement and the Director Plan. The Shares, when issued to Director upon the exercise of the Option, shall be fully paid and non-assessable. 
 2. Purchase Price. The purchase price of the Shares shall be
$             per Share. 
 3. Exercise of Option. The
period during which the Option is in effect (“Option Period”) shall commence on                     , 2007. The Option Period
shall terminate on                     , 2014. No portion of the Option may be exercised prior to
                    , 2008. Subject to the provisions of the Director Plan relating to suspension or termination from the Director
Plan, the Option will be available for exercise on                     , 2008, whereupon the Option will be fully vested. 

If the Director desires to exercise the Option, Director must deliver written notice to Stock Plan Administration of Valero substantially in the form
of the attached Form A (“Exercise Notice”). The Option must be exercised in accordance with one of the methods for exercise set forth in the attached form of Exercise Notice. The date on which the Exercise Notice is received by
Valero will be the “Exercise Date.” The completed Exercise Notice must include the number of Shares with respect to which the Option is being exercised. Payment for the Shares will be made at Valero’s San Antonio offices. 

If any law or regulation requires Valero to take any action with respect to the Shares specified in the Exercise Notice, then the date of delivery of
the Shares against payment shall be extended for the period necessary to take such action. In the event of any failure by Director to pay for the number of Shares specified in the Exercise Notice on the Settlement Date, as the same may be extended
as provided above, the exercise of the Option with respect to such number of Shares shall be treated as if it had never been made. 
 4.
Director Plan Incorporated by Reference. The Director Plan is incorporated herein, and by this reference, is made a part hereof for all purposes. The Director Plan contains detailed provisions relating to, among other things, forfeiture of this
Option under certain circumstances, adjustment of Shares in the event of certain changes in capitalization, and other matters of importance to Director. Director warrants and agrees that he or she has received and read a copy of the Director Plan or
a Director Plan Summary relating thereto, and that all rights granted hereunder are subject to the more detailed provisions of the Director Plan. 
 5. Limitation of Rights of Director. Director shall have no rights with respect to any Shares not expressly conferred by the Director Plan or this Agreement. 
 6. No Assignment. This Agreement and the Option granted hereunder are of a personal nature and, without prior written approval from the
Compensation Committee of the Board of Directors, the option shall not be transferable by Director except by will or under the laws of descent and distribution, and shall be exercisable, during the Director’s lifetime, only by Director.

 7. Successors. This Agreement shall be binding upon any successors of Valero and the heirs, successors and legal representatives of
Director. 

 8. Direct Registration. Director agrees that in lieu of stock certificates, any Shares issuable in
connection with the exercise of the Option may be issued in uncertificated form pursuant to the Direct Registration Service of Valero’s stock transfer agent. 

 The “Form A” referenced in Section 3 of the foregoing agreement has been omitted from this
Exhibit 10.04. A copy of the omitted Form A will be furnished to the Commission upon request.Royalty Interest Assignment Agreement

 Exhibit 10.1 
 NOTE: Portions of this Exhibit are the subject of a Confidential Treatment Request by the Registrant to the Securities and Exchange Commission (the “Commission”). Such portions have been redacted and are marked with a
“[***]” in place of the redacted language. The redacted information has been filed separately with the Commission. 
 ROYALTY
INTEREST ASSIGNMENT AGREEMENT 
 between 
 EPOCH BIOSCIENCES, INC. 
 as Assignor 
 and 
 DRUG ROYALTY TRUST 9 
 as Assignee 
 and 
 NANOGEN, INC. 
 as Guarantor

 September 29, 2006 

 ROYALTY INTEREST ASSIGNMENT AGREEMENT 
 THIS AGREEMENT is made and entered into as of September 29, 2006, 
 BETWEEN: 
 EPOCH BIOSCIENCES, INC., 
 a corporation organized and existing under the laws 
 of State of Delaware 
 (hereinafter referred to as “Epoch” or “Assignor”) 
                                 - and - 
 DRUG ROYALTY TRUST 9, 
 a Delaware trust acting through its manager 
 (hereinafter referred to as
“Assignee”). 
                                 - and - 
 NANOGEN, INC., 
 a corporation organized and existing under the laws 
 of the State of Delaware 
 (hereinafter referred to as “Nanogen” or “Guarantor”). 
 WHEREAS Assignor is a party to a Second Amended and Restated Collaboration, License and Supply agreement with Applera Corporation (the
“Licensee”) dated as of August 17, 2000, as amended by the First Side Agreement dated October 31, 2001, the Amendment No. 1 to the Second Amended and Restated Collaboration, License and Supply Agreement dated
July 26, 2002 and Amendment No. 2 to the Second Amended and Restated Collaboration, License and Supply Agreement dated as of December 31, 2005 (as amended, the “License Agreement”); 
 AND WHEREAS Assignor wishes to sell, assign, convey and transfer to Assignee, and Assignee wishes to purchase from Assignor, certain rights under
the License Agreement, upon and subject to the terms and conditions hereinafter set forth; 
 AND WHEREAS Nanogen as the parent
corporation of Epoch has agreed to guarantee the payment by Epoch of the Minimum Royalty Payments (as defined herein); 
 NOW THEREFORE
for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows: 

 ARTICLE 1 
 INTERPRETATION 
  

	1.1	Definitions 

 In this Agreement: 
 “Acquired Royalty Payments” means the First Stream Royalty Payments together with the Second Stream Royalty Payments; 
 “Affiliate” means a Person that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under
common control with, the Person specified; 
 “Agreement” means this Royalty Interest Assignment Agreement, the recitals, all
attached exhibits and schedules, and any agreement, exhibit or schedule supplementing or amending this Agreement. All uses of the words “hereto”, “herein,” “hereof,” “hereby” and “hereunder” and
similar expressions refer to this Agreement and not to any particular section or portion of it; 
 “Applicable Law” means, in
respect of any Person, property, transaction or event, any statute, law, ordinance, rule, regulation, regulatory policy, order, judgment or decree applicable to that Person, property, transaction or event; 
 “Assigned Interests” has the meaning specified in Section 2.1; 
 “Assignee” has the meaning specified in the introduction to this Agreement; 
 “Assignor” has the meaning specified in the introduction to this Agreement; 
 “Authorization” has the meaning specified in Section 7.2(e); 
 “Business Day” means any day of the week other than a Saturday, Sunday or a day observed as a statutory or civic holiday in New York, New
York; 
 “Closing Document” means any document, instrument, undertaking or agreement made or delivered pursuant to or in
connection with this Agreement; 
 “control” means, in respect of a legal Person, direct or indirect legal or beneficial
ownership of more than 50% of the voting interests in or the equity or participation interests in, or the right to appoint more than 50% of the directors or the management of, such Person; 
 “Effective Date” means the date hereof; 
 “Encumbrances” means liens, charges, security interests, mortgages, options, privileges, pledges, trusts or deemed trusts (whether contractual, statutory or otherwise) and any other encumbrance, right
or claim of any other person of any kind whatsoever; 
 “First Stream Royalty Payments” has the meaning specified in Section
2.1(a); 
 “Governmental Agency” means any domestic or foreign government whether federal, state, provincial or
municipal and any governmental agency, governmental authority, governmental tribunal or governmental commission of any kind whatever; 
 “including,” when used herein or in any Closing Document, means “including without limitation” and shall not be construed to limit any general statement which it follows to the specific or similar items or matters
immediately following it; 
 “Know-How” means Licensed Know-How, as that term is defined in the License Agreement;

 “License Agreement” has the meaning specified in the recitals to this Agreement; 
 “Licensee” has the meaning specified in the recitals to this Agreement; 
 “Licensee Acknowledgment” has the meaning specified in Section 7.2; 
 “Lock Box Account” has the meaning specified in Section 3.2(a); 
 “Lock Box Agreement” has the meaning specified in Section 3.2(b); 
 “Minimum Royalty Payments” has the meaning specified in Section 3.4; 
 “Notice” has the meaning specified in Section 10.6; 
 “Parties” means Epoch, Assignee and Nanogen, collectively, and “Party” means any one of them; 
 “Patents” means the Licensed Patents and Related Patents, as those terms are defined in the License Agreement, including those Patents and patent applications set forth on Exhibit C attached hereto;

 “Permitted Encumbrances” means (i) any license in intellectual property granted prior to, or granted after the date
hereof in accordance with Section 8.5(b)(iii), by Assignor, including patents and trademarks held by Assignor, that does not interfere with, or cause a diminution of value of, the Assigned Interests, and (ii) the Security Interest; 

“Person” includes an individual, corporation, partnership, limited partnership, limited liability partnership, limited liability
company, joint venture, association, trust, unincorporated organization, or any other legal entity; 
 “Product” means a
Licensed Product, as that term is defined in the License Agreement; 
 “Purchase Price” has the meaning specified in section
3.1; 
 “Quencher Agreement” means the license and supply agreement between Epoch and the Licensee dated as of
September 2, 2003 in respect of Epoch's EclipseTM product as amended by Amendment No. 1 to the Quencher 

 
License and Supply Agreement dated September 2, 2003 and as further amended by Amendment No. 2 dated December 31, 2005, as such agreement may
be further amended from time to time; 
 “Reports” means (i) any notices of breach of the License Agreement and any
notices of infringement or claims in respect of the Patents and Know-How and (ii) all reports, statements, calculations and certifications referenced in and deliverable under Section 5.06 of the License Agreement relating to the
calculation and payment of the Royalties, and for greater certainty “Reports” does not include any of the foregoing documents or any information in any of the foregoing documents that does not relate to the calculation and payment of
Royalties, such as, for example, the selling price of the Bare Probes for Large Sale Orders under Section 6.02 of the License Agreement; 
 “Royalties” means all of the royalties payable to Epoch under the License Agreement in respect of (i) Net Sales (as defined in the License Agreement) made and (ii) Net Revenues (as defined in the License
Agreement) received, as calculated in accordance with Article 5 and section 4.02 respectively of the License Agreement, together with any collections or recoveries receivable or lump sum payments payable in lieu thereof including in connection with
(a) any litigation to enforce the License Agreement, the Patents or the Know-How, (b) any interest payable thereon pursuant to Section 5.07 of the License Agreement, and (c) any deficiency payment plus interest thereon as
described in Section 5.10 of the License Agreement; 
 “Second Stream Royalty Payments” has the meaning specified in
Section 2.1(b); 
 “Security Agreement” has the meaning specified in Section 7.2(c); 
 “Security Interest” means the security interest granted pursuant to the Security Agreement; 
 “Term” has the meaning specified in Section 1.9; 
 “Third Party” means any Person other than Epoch or Assignee, and their respective Affiliates and Assignee's co-investors; 
 “Transmission” means any electronic means of sending messages, including facsimile transmission, which produces a paper record; and 
 “USPTO” mean the United States Patent and Trademark office. 
  

	1.2	Headings 

 The division of this Agreement
into articles, sections and subsections and the insertion of headings are for convenience of reference only and shall not affect the construction or interpretation of this Agreement. Unless otherwise specified, references in this Agreement to
Sections, Exhibits and Schedules are references to sections of and schedules and exhibits to this Agreement. 
  

	1.3	Number and Gender 

 Unless otherwise
specified in this Agreement, words in the singular number include the plural and vice-versa and words in one gender include all genders. 
  

	1.4	Entire Agreement 

 This Agreement, together
with the Closing Documents, constitutes the entire agreement between the Parties pertaining to the subject matter hereof and supersedes all prior agreements, negotiations, discussions and understandings, written or oral. There are no
representations, warranties, conditions, other agreements or acknowledgements, whether direct or collateral, or express or implied, that form part of or affect this Agreement, or which induced any Party to enter into this Agreement or on which
reliance is placed by any Party, except as specifically set forth in this Agreement or in the Closing Documents. 
  

	1.5	Applicable Law; Waiver of Jury Trial 

 This
Agreement shall be governed by, and interpreted and enforced in accordance with, the laws of the State of New York, without giving effect to the principles of conflicts of law thereof except as set forth in Section 5-1401 of the New York
General Obligations Law. 

 EACH PARTY HEREBY AGREES NOT TO ELECT A TRIAL BY JURY OF ANY ISSUE TRIABLE OF RIGHT BY JURY, AND WAIVES
ANY RIGHT TO TRIAL BY JURY FULLY TO THE EXTENT THAT ANY SUCH RIGHT SHALL NOW OR HEREAFTER EXIST WITH REGARD TO THIS AGREEMENT, OR ANY CLAIM, COUNTERCLAIM OR OTHER ACTION ARISING IN CONNECTION HEREWITH. THIS WAIVER OF RIGHT TO TRIAL BY JURY IS GIVEN
KNOWINGLY AND VOLUNTARILY BY EACH PARTY, AND IS INTENDED TO ENCOMPASS INDIVIDUALLY EACH INSTANCE AND EACH ISSUE AS TO WHICH THE RIGHT TO A TRIAL BY JURY WOULD OTHERWISE ACCRUE. EACH PARTY IS HEREBY AUTHORIZED TO FILE A COPY OF THIS PARAGRAPH IN ANY
PROCEEDING AS CONCLUSIVE EVIDENCE OF THIS WAIVER. 
  

	1.6	Consent to Jurisdiction 

 Each of Assignor,
Assignee and Guarantor (a) hereby irrevocably submits to the jurisdiction of the United States District Court for the Southern District of New York for the purposes of any suit, action or proceeding arising out of or relating to this Agreement
and to the extent that such United States district court lacks jurisdiction despite the consent herein, to the jurisdiction of the courts of the State of New York sitting in New York County and the appellate courts therefrom, and (b) hereby
waives, and agrees not to assert in any such suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of such court, that the suit, action or proceeding is brought in an inconvenient forum or that the venue of the
suit, action or proceeding is improper. Each of the Assignor and Assignee consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address in effect for notices to it under this Agreement
and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing in this Section 1.6 shall affect or limit any right to serve process in any other manner permitted by law. 
  

	1.7	Currency 

 Unless otherwise specified in this
Agreement, all statements of or references to monetary amounts in this Agreement are references to the lawful currency of the United States of America and all sums of money to be paid or calculated pursuant to this Agreement shall be calculated and
paid in United States currency. 
  

	1.8	Exhibits and Schedules 

 The Exhibits and
Schedules attached hereto form an integral part of this Agreement. 
  

	1.9	Term 

 The term (the “Term”)
of this Agreement shall commence as of the Effective Date and shall continue until the date of receipt by Assignee of all Acquired Royalty Payments, including the Acquired Royalty Payment for the quarterly period ending on and including
December 31, 2011 and the receipt by Assignee of all Reports in respect of Acquired Royalty Payments. 

 ARTICLE 2 
 PURCHASE AND ASSUMPTION 
  

	2.1	Purchase of Assigned Interests 

 Assignor
hereby sells, assigns and transfers to Assignee and Assignee hereby purchases from Assignor an undivided interest in all right, title and interest of Assignor in and to the rights set forth in Subsections (a) through (c) below
(collectively, the “Assigned Interests”): 
  

	 	(a)	the right to receive one hundred percent (100%) of the Royalties during the period from and including July 1, 2006 up to and including December 31, 2011 and
designated on Exhibit A as First Stream Royalty Payments (the “First Stream Royalty Payments”; 

  

	 	(b)	the right to receive [***] percent [***] of the Royalties during the period from and including July 1, 2006 up to and including December 31, 2011 and designated on Exhibit
A as Second Stream Royalty Payments (the “Second Stream Royalty Payments”); and 

  

	 	(c)	the right to receive any and all Reports. 

 ARTICLE 3

 PAYMENTS 
  

	3.1	Payment of Purchase Price 

 In consideration
for the Assigned Interests, Assignee shall concurrent with the execution of this Agreement pay to Epoch $20,000,000 (the “Purchase Price”). All payments shall be paid to or to the order of Epoch by wire transfer of same day funds to
the bank account designated by Epoch or its authorized agent. 
  

	3.2	Remittances of Royalties 

 (a) Payments of
the Acquired Royalty Payments shall be made directly to a lock box account (the “Lock Box Account”) held with HSBC as agent, but otherwise in the manner provided in the License Agreement and the Assignor shall so direct the Licensee
and any of Licensee's customers with licences under Section 4.02 of the License Agreement. 
 (b) Assignee and Assignor shall enter into
a lock box account agreement (the “Lock Box Agreement”) with HSBC as agent, which Lock Box Agreement shall provide for the disbursement of funds to Assignee or to Assignor from the lock box account in accordance with the payment
provisions of this Agreement. 
 (c) If at any time Assignor receives or has received any Acquired Royalty Payment, Assignor shall be deemed
to be holding such funds in trust for Assignee and shall forthwith upon receipt of such funds, deliver the same to Assignee without deduction or set-off. 
 *** Confidential portions omitted and filed separately with the Commission. 

 (d) If at any time Assignee receives or has received any payment or other monies paid into the Lock Box
Account that are not in respect of the Assigned Interests or that Assignee is not otherwise entitled to, Assignee shall be deemed to be holding such funds in trust for Assignor and shall forthwith upon receipt of such funds, deliver the same to
Assignor without deduction or set-off. 
  

	3.3	Offset 

 (a) Assignor agrees that the
Assigned Interests and all payments in respect thereof shall be free of any claim as between Assignor and Licensee for offset, true up or deficiency, whether arising prior to or after the Effective Date and agrees to hold Assignee harmless in
respect of any such offset, true up or deficiency. 
 (b) If under the terms of the License Agreement, Licensee is entitled to reduce any
amount payable thereunder in respect of the Assigned Interests by amounts paid to Assignor in respect of the Quencher Agreement, Assignor agrees that any such reduction shall constitute a set-off under (a) above and shall hold Assignee harmless
in respect thereof. 
  

	3.4	Minimum Royalties 

 (a) If in any year of the
calendar years 2006 through and including 2011 the Acquired Royalty Payments for that year are less than the minimum royalty payment for that year as specified on Schedule A (each a “Minimum Royalty Payment” and collectively, the
“Minimum Royalty Payments”) then Epoch shall within 45 days of the end of such calendar year pay to Assignee an amount equal to the difference between the Acquired Royalty Payment for that year and the Minimum Royalty Payment for
that year. 
 (b) If the Assignor has made a Minimum Royalty Payment in respect of a calendar year and thereafter additional Royalties are
paid by Licensee in respect of that calendar year, Assignee shall be entitled to the excess of those Royalties over the Minimum Royalty Payment and Assignor shall be entitled to the amounts up to the Minimum Royalty Payment paid by Assignor to
Assignee. 
 ARTICLE 4 
 REPRESENTATIONS AND WARRANTIES OF ASSIGNOR 
 Assignor represents and warrants as at the Effective Date to Assignee as
follows, and acknowledges that Assignee is relying on such representations and warranties in entering into this Agreement: 
  

	4.1	Corporate Matters 

 (a) Epoch is a
corporation duly incorporated and in good standing under the laws of the State of Delaware. 
 (b) Assignor has all necessary corporate power,
right and authority to carry on its business as it is presently conducted. 
 (c) Assignor has all necessary corporate power, right and
authority to execute and deliver, and to observe and perform its covenants and obligations under this Agreement, the License Agreement and each of the Closing Documents to which it is a party. 

 (d) Assignor has taken all corporate action necessary to authorize the execution and delivery of, and the
observance and performance of its covenants and obligations under this Agreement and the Closing Documents to which it is a party. 
 (e)
This Agreement and each Closing Document to which Assignor is a party has been or will be duly executed and delivered by Assignor, and this Agreement and each Closing Document to which Assignor is a party constitutes or will constitute a legal,
valid and binding obligation of Assignor enforceable against it in accordance with its terms subject to applicable bankruptcy, insolvency, reorganization, moratorium or other laws affecting the enforcement of creditors' rights or by general
principles of equity. 
 (f) Assignor is not insolvent and no proceedings have been taken or authorized by Assignor, to the knowledge of
Assignor by any other Person, with respect to the bankruptcy, insolvency, liquidation, dissolution or winding up of Assignor. 
  

	4.2	Title 

 (a) Assignor is the exclusive owner
of all legal and equitable title, free and clear of all Encumbrances (i) to the Assigned Interests, (ii) other than Permitted Encumbrances, to the Patents and (iii) to the Know-How. 
 (b) The License Agreement is free and clear of all Encumbrances other than Permitted Encumbrances granted by or imposed in respect of Assignor or, to the
knowledge of Assignor, the Licensee. 
  

	4.3	License Agreements 

 (a) Each of the License
Agreement and the Quencher Agreement, a copy of each of which together with all amendments thereto is attached as Exhibit B hereto, and each of which is a true and complete copy of the original thereof, is in full force and effect and has not
been further amended. The License Agreement is a valid, legal and binding obligation of Epoch and, to the knowledge of Epoch, of the Licensee, enforceable against each party thereto in accordance with its terms. Neither Assignor nor, to the
knowledge of Epoch, Licensee is in material default of any of its respective obligations under the License Agreement. Neither Licensee nor Assignor has waived any rights or defaults under the License Agreement that would adversely affect in any
material respect the Assigned Interests, the License Agreement, the Patents, the Products or the Know-How and no event has occurred which, after the giving of notice or the lapse of time or both, would constitute a material default or breach by
Assignor or, to the knowledge of Epoch, by the Licensee of the License Agreement. 
 (b) Assignor has not received any notice, and is not
otherwise aware of, any actual or potential defense or claim (including any claim of recoupment) of the Licensee that could be asserted against Assignee as assignee of the Assigned Interests. 
 (c) Assignor has provided to Assignee a true and complete copy of each report and certificate delivered by Licensee pursuant to Section 5.06 of the
License Agreement. 

 (d) the License Agreement is the only agreement (other than this Agreement) that the Assignor is a party
to with respect to the Assigned Interests. 
 (e) the Patents licensed under the License Agreement for the Exclusive Licensed Field (as that
term is defined in the License Agreement) are not licensed under any other agreement other than the Quencher Agreement for any field outside of the Exclusive Licensed Field. After the Effective Date, any royalty under any of the Patents payable to
Assignor arising from the sale of any Product which is a licensed product covered by both the License Agreement and the Quencher Agreement shall be a Royalty subject to, and shall be paid to Assignee under, the terms of this Agreement. 

(f) Licensee has no prepayments of Royalties remaining unapplied under the License Agreements, including pursuant to Section 5.01 of the License
Agreement. 
 (g) Other than pursuant to the Authorization, no agent has been appointed by Assignor pursuant to Section 5.10 of the
License Agreement for the purpose of inspecting records relating to the Assigned Interests. 
  

	4.4	Intellectual Property 

 (a) Exhibit C sets
forth a complete list of all patent applications and patents within the Patents, including the status of each patent and patent application. No Person has challenged the validity or enforceability of any of the Patents. To the knowledge of Assignor,
there is no infringement of the Patents by any Person. Assignor has not received any demand or claim in writing by any Person that (i) such person has any ownership interest in any of the Patents, (ii) any of the Patents are, or may be
invalid or (iii) that the Product infringes upon or may infringe upon or otherwise interferes with any patent or other right of any kind of any third party and Epoch is not aware of any basis for any Person to claim that they have any interest
in any of the Patents. To the knowledge of Assignor, the Patents are valid and enforceable and all appropriate fees have been paid. To the knowledge of Assignor, the naming of inventors in any of the Patents is correct and occurred without any
deceptive intent. To the knowledge of Assignor, neither the Products nor any of the Products sold by Licensee infringe or interfere with any patent or other right of any kind of any third party. Assignor has disclosed to Assignee all third party
patents relevant to the Assigned Interests for which Assignor has requested a legal opinion concerning validity or non-infringement. Other than pursuant to the License Agreement and the Quencher Agreement Epoch has not granted any Person the right
under the Patents to develop, manufacture, distribute, import, make, use, market or sell the Products or any other product that would infringe the Patents. 
 (b) To the knowledge of Assignor, all material Know-How is owned by Assignor, and has been treated as proprietary and confidential and in a manner consistent with protecting its trade secrets from disclosure or
misappropriation. To the knowledge of Assignor, no third party has a claim or has claimed any ownership rights or received any demand or claim by any person that any of the Know-How is infringing any intellectual property rights of any third party.

	4.5	Absence of Conflicting Agreements 

 Neither
the execution and delivery of this Agreement or of any of the Closing Documents, nor the observance and performance by Assignor of any covenant or obligation under this Agreement or any Closing Document to which it is a party, or the consummation of
any of the transactions contemplated hereby and thereby, contravenes or results in, or will contravene or result in, a violation of or a default under (with or without the giving of notice or lapse of time, or both) or in the acceleration of any
obligation under: 
  

	 	(a)	any Applicable Law; 

  

	 	(b)	the certificate of incorporation, by-laws or similar organizational documents of Assignor or any directors', shareholders', or members’ resolutions of such Party; or

  

	 	(c)	any material instrument, contract, lease, license or other agreement to which Assignor is a party, or by which it or its business or property is bound or affected.

  

	4.6	Consents and Approvals 

 Other than the
Licensee Acknowledgement, no consent, approval, license, order or authorization, registration, declaration or filing with or of any Governmental Agency or other Person is required by Assignor in connection with: 
  

	 	(a)	the execution and delivery by Assignor of this Agreement and the Closing Documents to which it is a party; 

  

	 	(b)	the observance and performance by Assignor of its obligations under this Agreement and the Closing Documents to which it is a party; or 

  

	 	(c)	the consummation of any of the transactions contemplated thereby. 

  

	4.7	Compliance with Applicable Law 

 Assignor has
conducted and is conducting its business in compliance with all Applicable Laws, and is not in violation of any Applicable Laws, except for violations which do not or will not (either individually or in the aggregate) adversely affect in any
material respect the Assigned Interests, the License Agreement, the Patents, the Products or Assignor's ability to perform its obligations under this Agreement. 
  

	4.8	Litigation 

 There is no claim, demand, suit,
action, cause of action, dispute, proceeding, litigation, investigation, grievance, arbitration, governmental proceeding or other proceeding, including appeals and applications for review, in progress against, by or relating to Assignor, the
Assigned Interests, the License Agreement, the Patents or the Products, which would invalidate the Agreement or limit Epoch's ability to carry out its obligations hereunder or materially adversely affect the Assigned Interests, the License
Agreement, the Patents or the Products, nor to the knowledge of Assignor, are any of the same pending or threatened. There is not presently outstanding against Assignor any judgment, decree, injunction, order or award of any court, Governmental
Agency or arbitrator that has, or could have, a material adverse effect on the Assigned Interests, the License Agreement, the Patents or the Products or such Party or its business or property. 

	4.9	Survival 

 The representations and warranties
in this Article 4 shall survive the Closing and the consummation of the transactions contemplated by this Agreement for the Term, except for representations as to title, which shall survive indefinitely. To the extent not performed by the Effective
Date, the covenants of Assignor in this Agreement shall survive the Closing and the consummation of the transactions contemplated by this Agreement for the Term and for a period of one year after the expiry of the Term. 
 ARICLE 5 
 REPRESENTATIONS AND
WARRANTIES OF ASSIGNEE 
 Assignee represents and warrants to Assignor as at the Effective Date and acknowledges that Assignor is
relying on such representations and warranties in entering into this Agreement: 
  

	5.1	Corporate Matters 

 (a) Assignee is a trust
duly formed and validly existing under the laws of the State of Delaware. 
 (b) Assignee has all necessary power and capacity to execute and
deliver, and to observe and perform its covenants and obligations under this Agreement and each of the Closing Documents to which it is a party. 
 (c) Assignee has taken all action necessary to authorize the execution and delivery of, and the observance and performance of its covenants and obligations under, this Agreement and the Closing Documents to which it is a party. 

(d) This Agreement and each Closing Document to which Assignee is a party has been or will be duly executed and delivered by Assignee, and this
Agreement and each Closing Document to which Assignee is a party, constitutes or will constitute a legal, valid and binding obligation of Assignee enforceable against it in accordance with its terms subject to applicable bankruptcy, insolvency,
reorganization, moratorium or other laws affecting the enforcement of creditors' rights or by general principles of equity. 
  

	5.2	Consents and Approvals 

 No consent,
approval, license, order or authorization, registration, declaration or filing with or of any Governmental Agency or other Person is required by Assignee in connection with: 
  

	 	(i)	the execution and delivery by Assignee of this Agreement and the Closing Documents to which it is a party; 

  

	 	(ii)	the observance and performance by Assignee of its obligations under this Agreement and the Closing Documents to which it is a party; or 

  

	 	(iii)	the consummation of any of the transactions contemplated thereby. 

	5.3	Absence of Conflicting Agreements 

 Neither
the execution and delivery of this Agreement or of any of the Closing Documents, nor the observance and performance by Assignee of any covenant or obligation under this Agreement or any Closing Document to which it is a party, or the consummation of
any of the transactions contemplated hereby and thereby, contravenes or results in, or will contravene or result in, a violation of or a default under (with or without the giving of notice or lapse of time, or both) or in the acceleration of any
obligation under: 
  

	 	(i)	any Applicable Law; 

  

	 	(ii)	the certificate of trust, trust agreement or similar organizational documents of Assignee or any directors’, shareholders’, members’ or trustees’ resolutions of
such Party; or 

  

	 	(iii)	any material instrument, contract, lease, license or other agreement to which Assignee is a party, or by which it or its business or property is bound or affected.

  

	5.4	Compliance with Applicable Law 

 Assignee has
conducted and is conducting its business in compliance with all Applicable Laws, and is not in violation of any Applicable Laws, except for violations which do not or will not (either individually or in the aggregate) adversely affect in any
material respect the Assignee's ability to perform its obligations under this Agreement. 
  

	5.5	Litigation 

 There is no claim, demand, suit,
action, cause of action, dispute, proceeding, litigation, investigation, grievance, arbitration, governmental proceeding or other proceeding, including appeals and applications for review, in progress against, by or relating to Assignee, which would
invalidate the Agreement or materially limit Assignee's ability to carry out its obligations hereunder nor to the knowledge of Assignee, are any of the same pending or threatened. There is not presently outstanding against Assignee any judgment,
decree, injunction, order or award of any court, Governmental Agency or arbitrator that has, or could have, a material adverse effect on the Assignee or its business or property. 
  

	5.6	Survival 

 The representations and warranties
in this Article 5 shall survive the Closing and the consummation of the transactions contemplated by this Agreement for the Term. To the extent not performed by the Effective Date, the covenants of Assignee in this Agreement shall survive the
Closing and the consummation of the transactions contemplated by this Agreement for the Term and for a period of one year after the expiry of the Term. 

 ARTICLE 6 
 REPRESENTATIONS AND WARRANTIES OF NANOGEN 
 Nanogen represents and warrants to Assignee as at
the Effective Date as follows, and acknowledges that Assignee is relying on such representations and warranties in entering into this Agreement: 
  

	6.1	Corporate Matters 

 (a) Nanogen is a
corporation duly incorporated and in good standing under the laws of the State of Delaware. 
 (b) Nanogen has all necessary corporate power,
right and authority to carry on its business as it is presently conducted. 
 (c) Nanogen has all necessary corporate power, right and
authority to execute and deliver, and to observe and perform its covenants and obligations under this Agreement, and each of the Closing Documents to which it is a party. 
 (d) Nanogen has taken all corporate action necessary to authorize the execution and delivery of, and the observance and performance of its covenants and obligations under this Agreement and the Closing Documents to
which it is a party. 
 (e) This Agreement and each Closing Document to which Nanogen is a party has been or will be duly executed and
delivered by Nanogen, and this Agreement and each Closing Document to which Nanogen is a party constitutes or will constitute a legal, valid and binding obligation of Nanogen enforceable against it in accordance with its terms subject to applicable
bankruptcy, insolvency, reorganization, moratorium or other laws affecting the enforcement of creditors’ rights or by general principles of equity. 
 (f) Nanogen is not insolvent and no proceedings have been taken or authorized by Nanogen, to the knowledge of Nanogen by any other Person, with respect to the bankruptcy, insolvency, liquidation, dissolution or
winding up of Nanogen. 
  

	6.2	Absence of Conflicting Agreements 

 Neither
the execution and delivery of this Agreement or of any of the Closing Documents, nor the observance and performance by Nanogen of any covenant or obligation under this Agreement or any Closing Document to which it is a party, or the consummation of
any of the transactions contemplated hereby and thereby, contravenes or results in, or will contravene or result in, a violation of or a default under (with or without the giving of notice or lapse of time, or both) or in the acceleration of any
obligation under: 
  

	 	(a)	any Applicable Law; 

  

	 	(b)	the certificate of incorporation, by-laws or similar organizational documents of Nanogen or any directors' or shareholders' resolutions of such Party; or 

 

	 	(c)	any material instrument, contract, lease, license or other agreement to which Nanogen is a party, or by which it or its business or property is bound or affected.

	6.3	Consents and Approvals 

 No consent,
approval, license, order or authorization, registration, declaration or filing with or of any Governmental Agency or other Person is required by Nanogen, in connection with: 
  

	 	(a)	the execution and delivery by Nanogen of this Agreement and the Closing Documents to which it is a party; 

  

	 	(b)	the observance and performance by Nanogen of its obligations under this Agreement and the Closing Documents to which it is a party; or 

  

	 	(c)	the consummation of any of the transactions contemplated thereby. 

  

	6.4	Compliance with Applicable Law 

 Nanogen has
conducted and is conducting its business in compliance with all Applicable Laws, and is not in violation of any Applicable Laws, except for violations which do not or will not (either individually or in the aggregate) adversely affect in any
material respect the Assigned Interests, the License Agreement, the Patents, the Products or Nanogen's ability to perform its obligations under this Agreement. 
  

	6.5	Litigation 

 There is no claim, demand, suit,
action, cause of action, dispute, proceeding, litigation, investigation, grievance, arbitration, governmental proceeding or other proceeding, including appeals and applications for review, in progress against, by or relating to Assignee, the
Assigned Interests, the License Agreement, the Patents or the Products, which would invalidate the Agreement or limit Nanogen's ability to carry out its obligations hereunder or materially adversely affect the Assigned Interests, the License
Agreement, the Patents or the Products, nor to the knowledge of Nanogen, are any of the same pending or threatened. There is not presently outstanding against Nanogen any judgment, decree, injunction, order or award of any court, Governmental Agency
or arbitrator that has, or could have, a material adverse effect on the Assigned Interests, the License Agreement, the Patents or the Products or Nanogen or its business or property. 
  

	6.6	Survival 

 The representations and warranties
in this Article 6 shall survive the Closing and the consummation of the transactions contemplated by this Agreement for the Term, except for representations as to title, which shall survive indefinitely. To the extent not performed by the Effective
Date, the covenants of Guarantor in this Agreement shall survive the Closing and the consummation of the transactions contemplated by this Agreement for the Term until and for a period of one year after the expiry of the Term. 
 ARTICLE 7 
 CLOSING

  

	7.1	Assignee Deliveries 

 Assignee shall deliver
to Epoch concurrent with delivery of this Agreement: 
  

	 	(a)	an amount of same day funds equal to the Purchase Price; 

	 	(b)	the duly executed and delivered counterpart to the Lock Box Agreement; 

  

	 	(c)	such other documents and instruments as Assignor may reasonably require to give effect to and carry out the transactions contemplated herein. 

  

	7.2	Assignor Deliveries 

 Assignor shall deliver
to Assignee concurrent with delivery of this Agreement: 
  

	 	(a)	a duly executed and delivered acknowledgment from Licensee in form and substance acceptable to the Assignee (the “Licensee Acknowledgment”);

  

	 	(b)	standard corporate authority and enforceability opinions on this Agreement, the Security Agreement and the Lock Box Agreement and a no conflict with laws opinion on the License
Agreement, from counsel to the Assignor each in form and substance satisfactory to the Assignee and its counsel; 

  

	 	(c)	a duly executed and delivered security agreement granting a security interest in the License Agreement, the Patents and the Know-How to (the “Security Agreement”)
Assignee as security for the performance of Assignor’s obligations hereunder; and 

  

	 	(d)	a duly executed and delivered Lock Box Agreement; 

  

	 	(e)	a duly executed and delivered authorization of Assignor appointing the Assignee or Assignee's nominee as Assignor's duly authorized agent for the purposes of inspecting
Licensee’s records relating to the Assigned Interests pursuant to Section 5.10 of the License Agreement (the “Authorization”); 

  

	 	(f)	a duly executed and delivered joint direction of Assignor and Assignee to Licensee to pay Royalties into the Lock Box Account; 

  

	 	(g)	in respect of both Assignor and Nanogen: 

  

	 	(i)	a current certificate of good standing from the secretary of State for the State of Delaware; 

  

	 	(ii)	certified resolutions authorizing the transaction; 

  

	 	(iii)	incumbency certificates; and 

  

	 	(iv)	such other documents and instruments as Assignee may reasonably require to give effect to and carry out the transactions contemplated herein. 

 ARTICLE 8 
 COVENANTS 
 The Parties covenant and agree as follows: 
  
  

	8.1	License Agreements 

 (a) Unless otherwise
agreed to in writing by the Parties, Assignor shall not, with respect to the Assigned Interests (i) forgive, release, or compromise any amount owed or to become owing with respect to the Assigned Interests on or after the Effective Date,
(ii) modify, waive, cancel or otherwise relinquish any of the Assigned Interests under the License Agreement, or (iii) amend, restate or novate either the License Agreement or the Quencher Agreement in a manner that could adversely affect,
or diminish the value of, the Assigned Interests. 
 (b) Upon becoming aware of any breach of the License Agreement arising with respect to
the Assigned Interests Assignor shall promptly notify Assignee in writing of such breach. 
 (c) During the Term and while any obligations
remain outstanding under this Agreement, Assignor will not terminate, modify, or subcontract or otherwise delegate its obligations under the License Agreement without the prior written consent of Assignee and will fulfill all of its supply
obligations under the License Agreement. 
 (d) Assignor will promptly provide to the Assignee copies of all Reports delivered under the
License Agreement during the Term or after the Term to the extent the Reports relate to Assigned Interests. 
 (e) Any royalty under any of
the Patents payable to Assignor arising from the sale of any Product which is a licensed product covered by both the License Agreement and the Quencher Agreement shall be a Royalty subject to, and shall be paid to Assignee under, the terms of this
Agreement. 
 (f) From time to time after the date hereof and during the Term, Assignee may change its nominee for purposes of the
Authorization, and upon request of Assignee Assignor shall promptly execute and deliver to Assignor a new Authorization in respect of Assignee's nominee as duly authorized agent. 
 (g) Epoch will not exercise its rights to inspect Licensee’s records relating to the Assigned Interests pursuant to the audit rights under
Section 5.10 of the License Agreement without the prior written consent of Assignee, which consent may be withheld in Assignee’s sole discretion. 
 (h) Assignee acknowledges that the License Agreement may be terminated by the Licensee (other than by reason of an act or omission of Epoch which caused such termination) in accordance with Section 9.02(c) of the
License Agreement, and that a termination of the License Agreement by Licensee in accordance with such section would not in and of itself constitute a breach of this Section 8.1 or any other provision of this Agreement. Assignor covenants that
in the event that the License Agreement is terminated by Licensee, Assignor will use its commercially reasonable efforts to enter into a license agreement for the Products within the Field of Use for the Patents specified in the Licence Agreement or
into a transaction to effect the exploitation for gain of those rights (in either case a “Replacement Agreement”), and to effect an assignment to Assignee of the royalties or proceeds under that Replacement Agreement in order 

 
to achieve as closely as possible an economic result no worse to the Assignee than if the License Agreement had not been terminated, and generally on terms
and conditions that are acceptable to Assignee acting reasonably. Assignor shall consult with Assignee prior to entering into any Replacement Agreement and shall keep Assignee informed as to the status of negotiations with respect to and completion
of the Replacement Agreement. 
  

	8.2	Maintenance and Access to Records 

 Assignor
agrees that it will retain all books and records and any other documents, information and files relating to the Products generated by it or delivered to it by the Licensee during the Term and thereafter for such period as is required by Applicable
Law. So long as such books and records and such other documents, information and files are retained by the Assignors, the Assignee or its authorized representatives shall have reasonable access thereto during the Term and for a period of six months
after the end of the Term (the “Clean-Up Period”), provided that if at the end of the Clean-Up Period there is a bona fide dispute between the parties with respect to any aspect of this Agreement, including as to whether or not the
Term or the Clean-Up Period has expired, then notwithstanding the expiry of the Clean-Up Period, this right shall continue. 
  

	8.3	Conduct of the Business 

 During the Term,
Assignor shall cause its business and other activities with respect to the Assigned Interests, the License Agreement, the Patents, the Products and the Know-How to be carried on in the ordinary course, consistent with past practice and shall not
take or permit to be taken any action that will have a material adverse effect on the Products. 
  

	8.4	True Sale 

 (a) Assignor and Assignee intend
and agree that the sale, assignment and transfer of the Assigned Interests under Section 2.1 (the “Assignment”) shall be, and is, a true sale by Assignor to Assignee that is absolute and irrevocable and that provides Assignee with
the full benefits of ownership of the Assigned Interests, and neither Assignor nor Assignee intends the transactions contemplated hereunder to be, or for any purpose to be characterized as, a loan from Assignee to Assignor. Assignor waives any right
to contest or otherwise assert that this Agreement is other than a true sale by Assignor to Assignee under Applicable Law, which waiver shall be enforceable against Assignor in any bankruptcy or insolvency proceeding relating to Assignor.

 (b) Assignor hereby consents to Assignee recording and filing, at Assignee's sole cost and expense, financing statements (and continuation
statements with respect to such financing statements when applicable) meeting the requirements of Applicable Law in such manner and in such jurisdictions as are necessary or appropriate to perfect the Assignment intended to be effected by this
Agreement, including precautionary filings customary in true sale transactions. 
  

	8.5	Patent Obligations 

 (a) During the Term,
Assignor shall, at is own cost, in accordance with its standard procedures and with good practice, and subject to the rights of Licensee under the License Agreement, use its commercially reasonable efforts (including making payment of appropriate
fees to the USPTO) to, (i) prosecute and maintain in full force and effect each pending patent application worldwide included in the Patents; (ii) maintain and keep in full force and effect any 

 
issued Patents in each of the countries worldwide in which Assignor has an issued patent, and (iii) maintain all Know-How relating to the Products in
strict confidence other than disclosure to Licensee in accordance with the License Agreement. Assignor shall provide notice to Assignee of all information relating to the prosecution and/or validity or enforceability of any patent or application in
the Patents, including all correspondence to and from the USPTO or any other patent office in which any patent application is pending or from which any patent has issued. If practicable, such notice to Assignee shall be in sufficient time to allow
Assignee to comment, or act pursuant to section (b) below, on matters which may have a material effect on the scope, validity, or enforceability of any of the Patents. 
 (b) Assignor shall not during the Term without the prior written consent of Assignee abandon any of the Patents or Know-How, or sell, transfer, assign or otherwise dispose of the Patents or Know-How to any Person and
shall not grant any licenses thereunder other than (i) the license in the License Agreement, (ii) the license in the Quencher Agreement, and (iii) any license for use outside the Field of Use as defined in the License Agreement or the
Quencher Agreement that does not and would not materially interfere with or impair the value of the Assigned Interests. Assignee shall have, at its option, the right to have Assignor assign to Assignee all right, title and interest in any Patent
that Assignor decides to abandon. 
 (c) Assignor hereby grants to Assignee an irrevocable power of attorney with power of substitution to
act in the place and stead of Assignor in performing the actions specified in (a)(i) and (a)(ii) above. Such power is acknowledged by Assignor to be coupled with an interest and shall be exercisable during the Term immediately upon Assignor's breach
of the covenant in (a)(i) and (a)(ii) above. Upon the expiry of the Clean-Up Period, this power shall terminate provided that if at the end of the Clean-Up Period there is a bona fide dispute between the parties with respect to any aspect of this
Agreement, including as to whether or not the Term or the Clean-Up Period has expired, then notwithstanding the expiry of the Clean-Up Period, this right shall continue. 
  

	8.6	Certain Conduct 

 During the Term, without
the prior written consent of Assignee, which consent shall not be unreasonably withheld, Assignor shall not: (i) create or suffer to exist any Encumbrance other than the Security Interest on any of the Assigned Interests or the License
Agreement; (ii) amend or terminate the License Agreement or fail to perform and fulfill its obligations under the License Agreement in accordance with the terms thereof if such amendment, termination or failure to perform would have a material
adverse affect on any of the Assigned Interests; (iii) sell, transfer, assign or otherwise dispose of any interest in the Patents other than pursuant to a Permitted Encumbrance, or (iv) agree to do any of the foregoing. 
  

	8.7	Indemnities 

 (a) Assignor hereby indemnifies
and agrees to hold Assignee harmless from any damages suffered or incurred by Assignee to the extent resulting from (i) any material breach of a representation or warranty of Assignor contained herein, or (ii) the material breach by
Assignor of any covenant contained in this Agreement or any of the Closing Documents, or (iii) any Encumbrance of any of the Assigned Interests or the License Agreement, other than any Encumbrance created by Assignee or a Permitted Encumbrance.
Assignee hereby indemnifies and holds Assignor harmless from any damages suffered or incurred by Assignor to the extent resulting from (i) any material breach of a representation or warranty of Assignee contained herein, or (ii) the
material breach by Assignee of any covenant contained in this Agreement or the Assignee Closing Documents. 

 (b) Assignor hereby indemnifies and agrees to hold Assignee harmless from any damages suffered or
incurred by Assignee to the Extent resulting from any breach of the License Agreement by a party thereto, other than (i) the failure of Licensee to pay the royalties owing thereunder where such failure to pay is not related to, resulting from
or in response to a breach of the License Agreement by Assignor or (ii) a breach of a covenant or representation by a party to the License Agreement related to or resulting from one or both of the parties' inability to market,
commercialize or exploit the Patents. 
  

	8.8	Third Party Claims Procedure 

 The
indemnified party shall give notice (the “Indemnity Notice”) to the indemnifying party specifying the particulars of any Third Party claim within ten (10) days after it receives notification of the claim; provided, however,
that failure to give such notice within such time period shall not prejudice the rights of the indemnified party except to the extent that the failure to give such notice materially adversely affects the ability of the indemnifying party to
defend the claim or to cure the breach of the representation, warranty, covenant or obligation giving rise to the claim. Subject to the terms of this Section 8.8, the indemnifying party shall have sole control over the defense and settlement
of such claim. The indemnifying party may not settle or compromise the claim without the prior written consent of the indemnified party unless such settlement or compromise (i) involves no payment (whether by cash, securities or other
instrument), assignment, granting of a license or admission of fault or wrongdoing by the indemnified party and (ii) the indemnified party receives a comprehensive general release of all claims from the applicable third parties. The indemnified
party shall provide to the indemnifying party, in confidence, all files, books, records and other information in its possession or control which may be relevant to the defense of such claim. The indemnified party shall co-operate in all reasonable
respects in the defense of such claim but at the expense of the indemnifying party. If the indemnifying party fails to diligently defend such claim throughout the period that such claim exists, its right to defend the claim shall terminate and the
indemnified party may assume the defense of such claim at the sole expense of the indemnifying party. In such event, the indemnified party may compromise or settle such claim, without the consent of the indemnifying party. 
 ARTICLE 9 
 GUARANTEE

  

	9.1	Guarantee 

 The Guarantor hereby
unconditionally, absolutely and irrevocably guarantees (the “Guarantee”) the full and punctual payment and performance by the Assignor as and when due of the obligations of the Assignor under this Agreement to pay, as and when due,
the Minimum Royalty Payments (the “Obligations”). 
  

	9.2	Nature of Guarantee 

 Subject to Section 9.5,
this Guarantee shall in all respects be a continuing, absolute, unconditional and irrevocable guarantee of payment or performance when due and not of collection, and shall remain in full force and effect until all Obligations have been indefeasibly
paid in full and all obligations of the Guarantor hereunder have been indefeasibly paid in full. The Guarantor guarantees that the Obligations will be paid or performed strictly in accordance 

 
with the terms of this Agreement and/or the relevant Closing Document, regardless of any law, regulation or order now or hereafter in effect in any
jurisdiction affecting any of such terms or the rights of Assignor with respect thereto. Assignee shall not be bound to avail itself of any remedies or to exhaust its recourse against Assignor or others or any security or other guarantees it may at
any time hold before being entitled to payment from the Guarantor. The Guarantor renounces all benefits of discussion and division. The liability of the Guarantor under the Guarantee shall be absolute, unconditional and irrevocable irrespective of,
and without being lessened or limited by: 
  

	 	(a)	the failure of Assignee to assert any claim or demand or to enforce any right or remedy against Assignor or any other Person (including any other guarantor) under the provisions of
any other document delivered under, pursuant to or in connection with this Agreement, or otherwise, or to exercise any right or remedy against any other guarantor of, or collateral securing, any of the Obligations; 

  

	 	(b)	any change in the time, manner or place of payment of, or in any other term of, all or any of the Obligations, or any other extension, compromise, indulgence or renewal of any
Obligation; 

  

	 	(c)	any reduction, limitation, variation, impairment, discontinuance or termination of the Obligations for any reason (other than by reason of any payment which is not required to be
rescinded), including any claim of waiver, release, discharge, surrender, alteration or compromise, and shall not be subject to (and the Guarantor hereby waives any right to or claim of) any defense or set-off, counterclaim, recoupment or
termination whatsoever by reason of the invalidity, illegality, non-genuineness, irregularity, compromise, unenforceability of, or any other event or occurrence affecting, the Obligations or otherwise (other than by reason of any payment which is
not required to be rescinded); 

  

	 	(d)	any amendment to, rescission, waiver or other modification of, or any consent to any departure from, any of the terms of this Agreement or other Closing Document;

  

	 	(e)	any addition, exchange, release, discharge, renewal, realization or non-perfection of any collateral security for the Obligations or any amendment to, or waiver or release or
addition of, or consent to departure from, any other guarantee held by Assignee as security for the Obligations; 

  

	 	(f)	the loss of or in respect of or the unenforceability of any other guarantee or other security which Assignee may now or hereafter hold in respect of the Obligations, whether
occasioned by the fault of Assignee or otherwise; 

  

	 	(g)	any change in the name of Assignor or in the constating documents, capital structure, capacity or constitution of Assignor, the bankruptcy or insolvency of Assignor, the sale of any
or all of Assignor's business or assets or Assignor being consolidated, merged or amalgamated with any other Person; or 

	 	(h)	any other circumstance (other than satisfaction in full of all Obligations) which might otherwise constitute a defense available to, or a legal or equitable discharge of, Assignor,
any surety or any guarantor. 

  

	9.3	Enforcement 

 Upon default in payment or
performance of the Obligations by Assignor under this Agreement or any Closing Document, the Guarantor shall forthwith, if the default is a payment default, pay to Assignee the total amount of the Obligations and the Assignee may apply the sum so
paid against such of the Obligations as Assignee may see fit and change any such application in whole or in part from time to time, and if the default is a performance default, perform such Obligation. 
  

	9.4	Guarantee in Addition to Other Security 

 The
Guarantee shall be in addition to and not in substitution for any other guarantee or other security which Assignee may now or hereafter hold in respect of the Obligations, and Assignee shall be under no obligation to marshal in favour of the
Guarantor any other guarantee or other security or any moneys or other assets which Assignee may be entitled to receive or may have a claim upon. 
  

	9.5	Release of Guarantee 

 The Guarantee shall be
released and the Assignor's Minimum Royalty Payments obligations shall cease to be effective in the event Licensee (i) is adjudged bankrupt or insolvent, (ii) makes an assignment in bankruptcy or otherwise for the benefit of creditors,
(iii) files a petition or proposal under bankruptcy, insolvency or similar legislation, or (iv) has instituted against it proceedings under bankruptcy, insolvency or similar legislation including for the appointment of a receiver or
trustee which proceedings are not vacated within 60 days thereof; 
  

	9.6	Reinstatement 

 The Guarantee shall continue
to be effective or shall be reinstated, as the case may be, if at any time any payment (in whole or in part) of any of the Obligations is rescinded or must otherwise be returned or restored by Assignee for any reason other than the insolvency,
bankruptcy or reorganization of Assignor provided it does not involve the wilful misconduct of Assignee, all as though such payment had not been made. 
  

	9.7	Waiver of Notice, etc. 

 The Guarantor hereby
waives promptness, diligence, notice of acceptance and any other notice with respect to any of the Obligations and the Guarantee. 

 ARTICLE 10 
 GENERAL 
  

	10.1	Confidentiality 

 During the term of this
Agreement and for five years thereafter, each of Assignee and Assignor and their respective Affiliates, shall not use, reveal or disclose to Third Parties (other than Assignee’s beneficiaries and the Assignor's and Assignee's respective
financial institutions, counsel and advisors and then only on a confidential basis) any information received from the other Party in connection with this Agreement (including any information or reports provided to Assignee or its Affiliates by
Licensee, and including the terms of this Agreement), without first obtaining the written consent of the disclosing or other Party, except as may be otherwise provided herein. This confidentiality obligation shall not apply to information which
(a) is or becomes a matter of public knowledge (other than as a result of a breach of this Agreement), (b) is already in the possession of the receiving Party, (c) is disclosed to the receiving Party by a Third Party having the right
to do so, or (d) is required by Applicable Law to be disclosed, including pursuant to applicable securities laws provided that if Assignor is required to file this Agreement or any other Closing Document in any registry of repository accessible
by the public, Assignor will use its commercially reasonable efforts to obtain confidential treatment for commercially sensitive information from such documents and shall co-operate and consult with Assignee in that regard. The Parties shall take
reasonable measures to assure that no unauthorized use or disclosure is made. 
  

	10.2	Amendment 

 This Agreement may be amended or
supplemented only by a written agreement signed by each Party. 
  

	10.3	Waiver of Rights 

 Any waiver of, or consent
to depart from, the requirements of any provision of this Agreement shall be effective only if it is in writing and signed by the Party giving it, and only in the specific instance and for the specific purpose for which it has been given. No failure
on the part of any Party to exercise, and no delay in exercising, any right under this Agreement shall operate as a waiver of such right. No single or partial exercise of any such right shall preclude any other or further exercise of such right or
the exercise of any other right. 
  

	10.4	Tender 

 Any tender of documents hereunder
may be made upon the Parties or their respective counsel and money shall be tendered by wire transfer of same day funds. 
  

	10.5	Expenses 

 Epoch agrees to pay all reasonable
costs and expenses of Assignee in connection with the transaction contemplated by this Agreement, any amendments or modifications of (or supplements to) this Agreement and any and all other documents furnished pursuant hereto or in connection
herewith, including the reasonable fees, and out-of-pocket expenses of counsel and consultants to Assignee, to a maximum of [***] (the “Cap”) provided that costs incurred by Assignee for the preparation by Assignee’s U.S.
bankruptcy counsel for Assignee of a memorandum of advice on the transactions contemplated by this Agreement shall not be included in, and shall be in addition to, any amounts paid under the Cap, as well as all reasonable costs and expenses
(including, without limitation, reasonable legal fees and expenses), if any, in connection with the enforcement of this Agreement. 
  

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 

 Assignor shall be responsible for and pay for its expenses in connection with the transactions contemplated by this
Agreement, including any counsel and broker fees. 
  

	10.6	Notices 

 Any notice, demand or other
communication (a “Notice”) required or permitted to be given or made hereunder shall be in writing and shall be sufficiently given or made if: 
  

	 	(a)	delivered in person during normal business hours of the recipient on a Business Day and left with a receptionist or other responsible employee of the recipient at the relevant
address set forth below; 

  

	 	(b)	sent by courier (overnight delivery); or 

  

	 	(c)	sent by Transmission, charges prepaid and confirmed by registered mail as provided in Subsection (b); 

 in the case of a Notice to Epoch at: 
 Epoch
Biosciences, Inc. 
 21720 23rd Drive SE #150 
 Bothwell, WA 98021 USA 
 Attn: Robert Saltmarsh and David Ludvigson 
 Facsimile No.: (425) 482-5550 
 and in the case of a Notice to Assignee at: 
 Drug Royalty Trust 9 
 In care of Drug Royalty
Corporation Inc. 
 in its capacity as manager 
 Royal Bank Plaza, Suite 3120, South Tower 
 Box 122, 200 Bay Street 
 Toronto, Ontario M5J 2J3 
 Canada 

Attn: Behzad Khosrowshahi 
 Facsimile No.
(416) 863-5161 
 with a copy to: 
 Davies Ward Phillips & Vineberg LLP 
 44th Floor 
 1 First Canadian Place 
 Toronto, Ontario M5X 1B1 
 Canada 

Attn: Rosemary Newman or Gillian R. Stacey 
 Facsimile No. (416) 863-0871 

 and in the case of a Notice to Nanogen: 
 Nanogen, Inc. 
 10398 Pacific Center Court

 San Diego, CA 92121 
 Toronto,
Ontario M5X 1B1 
 Canada 
 Attn:
Robert Saltmarsh and David Ludvigson 
 Facsimile No. (858) 410-4949 
 Any Notice so given shall be deemed to have been given and to have been received (a) on the day of delivery in person or by courier, if so delivered,
and (b) on the day following the day Notice was sent by Transmission, provided such day is a Business Day and if not, on the first Business Day thereafter. Addresses for Notice may be changed by giving notice in accordance with this Section
10.6. 
  

	10.7	Assignment 

  

	(a)	Upon notice in writing to Assignor, this Agreement and all of the rights of Assignee under this Agreement and the Assigned Interests and the Closing Documents shall be assignable by
Assignee without restriction. 

  

	(b)	Neither this Agreement, nor any or all of the rights or obligations hereunder shall be assignable by Assignor without the prior written consent of Assignee, which consent shall not
be unreasonably withheld provided that Epoch may without the prior consent of Assignee but with prior written notice assign this Agreement together with all of its rights hereunder to an Affiliate of Epoch, provided that such Affiliate assumes all
of Epoch's obligations hereunder and is at least as credit-worthy as Epoch, and further provided that if at any time such Affiliate ceases to be an Affiliate of Epoch, then all rights and obligations under this Agreement shall revert to Epoch or
Epoch’s successor. 

  

	(c)	This Agreement shall inure to the benefit of and be binding upon the Parties and their respective successors (including any successor by reason of merger, reorganization, sale of
assets or statutory arrangement of any Party) and permitted assigns. 

  

	10.8	Further Assurances 

 Each Party shall do such
acts and shall execute such further documents, conveyances, deeds, assignments, transfers and the like, and will cause the doing of such acts and will cause the execution of such further documents as are within its power as any other Party may in
writing at any time and from time to time reasonably request be done and/or executed, in order to give full effect to the provisions of this Agreement and the Closing Documents. 
  

	10.9	Independent Parties 

 Nothing contained in
this Agreement shall in any way or for any purpose constitute any Party a partner or agent or legal representative of any other Party in the conduct of any business or otherwise or a member of a joint venture or joint enterprise or create any
fiduciary relationship among them. Except as expressly provided herein, no Party shall have any authority to act for or to assume any obligation or responsibility on behalf of any other and no Party shall have any authority to bind any other Party
to act or to undertake any obligation or responsibility whatsoever. 

	10.10 Further	Transactions 

 If Assignor proposes to enter
into a further assignment or sale transaction similar in nature to the transactions contemplated by this Agreement in respect of any Royalties other than the Acquired Royalty Payments, Assignee shall have a right of first refusal and a right of last
offer in respect of any such further transactions. 
  

	10.11 Public	Announcements 

 The Parties agree that no
public announcements concerning the transactions contemplated herein will be made by any Party, except as may be necessary, in the opinion of counsel to the Party making such disclosure, to comply with the requirements of any Applicable Law,
including applicable Securities Laws and subject to Section 10.1. If any such public statement or release is so required concerning the transactions contemplated herein, the Party making such disclosure shall consult with the other Party prior
to making such statement or release, and the Parties shall use reasonable efforts, acting in good faith, to agree upon a text for such statement or release which is satisfactory to all Parties. 
  

	10.12 Severability	

 If any covenant, obligation or provision of this
Agreement or the application thereof to any Person or circumstance shall, to any extent, be invalid or unenforceable, the remainder of this Agreement or the application of such covenant, obligation or agreement to Persons or circumstances, other
than those as to which it is held invalid or unenforceable, shall not be affected thereby and each covenant, obligation and provision of this Agreement shall be separately valid and enforceable to the fullest extent permitted by law. 
  

	10.13 Counterparts	

 This Agreement may be executed in any number of
counterparts and each such executed counterpart shall be deemed to be an original. All executed counterparts when taken together shall constitute one and the same agreement. 
  

	10.14 Facsimile	Execution 

 To evidence the fact that it has
executed this Agreement, a Party may send a copy of its executed counterpart to the other Party by facsimile Transmission and that Party shall be deemed to have delivered this Agreement on the date it sent such facsimile Transmission. In such event,
such Party shall forthwith deliver to the other Party the counterpart of this Agreement executed by such Party. 
 SIGNATURE PAGES TO FOLLOW
THIS PAGE 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their
respective authorized officers as of the date first above written. 
  

					
	EPOCH BIOSCIENCES, INC.
		
	by	 	/s/ ROBERT SALTMARSH
		 	Name:	 	Robert Saltmarsh
		 	Title:	 	Chief Financial Officer

  

							
	DRUG ROYALTY TRUST 9,
		
	by	 	DRUG ROYALTY CORPORATION INC., its Manager,
			
		 	by	 	/s/ BEHZAD KHOSROWSHAHI
		 		 	Name:	 	Behzad Khosrowshahi
		 		 	Title:	 	President and Chief Executive Officer

  

					
	NANOGEN, INC.
		
	by	 	/s/ DAVID LUDVIGSON
		 	Name:	 	David Ludvigson
		 	Title:	 	President and Chief Operating Officer

 EXHIBIT A 
 ROYALTY PAYMENT STREAMS 
 First Stream Royalty Payments (in millions) 

 

						
	 Calendar
Year
	  	Royalties
Payable	  	Minimum
Royalty
Payment
	 2006
	  	[***]	  	$	1.82 M
	 2007
	  	[***]	  	$	4.30 M
	 2008
	  	[***]	  	$	4.82 M
	 2009
	  	[***]	  	$	5.20 M
	 2010
	  	[***]	  	$	5.41 M
	 2011
	  	[***]	  	$	5.41 M

 Second Stream Royalty Payments (in millions) 
  

			
	 Calendar Year
	 	 Royalties Payable

	 2006
	 	greater than [***]
	 2007
	 	greater than [***]
	 2008
	 	greater than [***]
	 2009
	 	greater than [***]
	 2010
	 	greater than [***]
	 2011
	 	greater than [***]

  

	***	CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 

 EXHIBIT B 
 LICENSE AGREEMENT AND QUENCHER AGREEMENT 
  

 EXHIBIT C 
 PATENTS AND PATENT APPLICATIONS

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}]]